The Journal of Neuroscience, July 11, 2007, 27(28):7429-7437; doi:10.1523/JNEUROSCI.1307-07.2007
Previous Article | Next Article 
Neurobiology of Disease
Lymphotoxin ß Receptor (LtßR): Dual Roles in Demyelination and Remyelination and Successful Therapeutic Intervention Using LtßRIg Protein
Sheila R. Plant,1,2 *
Heather A. Iocca,1 *
Ying Wang,1
J. Cameron Thrash,4
Brian P. O'Connor,1
Heather A. Arnett,1,2
Yang-Xin Fu,5
Monica J. Carson,4 and
Jenny P.-Y. Ting1,2,3
1Lineberger Comprehensive Cancer Center, 2Neuroscience Center, and 3Department of Microbiology-Immunology, University of North Carolina, Chapel Hill, North Carolina 27599, 4Division of Biomedical Sciences, University of California, Riverside, California 92521, and 5Department of Pathology, The University of Chicago, Chicago, Illinois 60637
Correspondence should be addressed to Dr. Jenny P.-Y. Ting, Lineberger Comprehensive Cancer Center, Campus Box 7295, University of North Carolina, Chapel Hill, NC 27599. Email: panyun{at}med.unc.edu
Inflammation mediated by macrophages is increasingly found to play a central role in diseases and disorders that affect a myriad of organs, prominent among these are diseases of the CNS. The neurotoxicant-induced, cuprizone model of demyelination is ideally suited for the analysis of inflammatory events. Demyelination on exposure to cuprizone is accompanied by predictable microglial activation and astrogliosis, and, after cuprizone withdrawal, this activation reproducibly diminishes during remyelination. This study demonstrates enhanced expression of lymphotoxin ß receptor (LtßR) during the demyelination phase of this model, and LtßR is found in areas enriched with microglial and astroglial cells. Deletion of the LtßR gene (LtßR/) resulted in a significant delay in demyelination but also a slight delay in remyelination. Inhibition of LtßR signaling by an LtßRIg fusion decoy protein successfully delayed demyelination in wild-type mice. Unexpectedly, this LtßRIg decoy protein dramatically accelerated the rate of remyelination, even after the maximal pathological disease state had been reached. This strongly indicates the beneficial role of LtßRIg in the delay of demyelination and the acceleration of remyelination. The discrepancy between remyelination rates in these systems could be attributed to developmental abnormalities in the immune systems of LtßR/ mice. These findings bode well for the use of an inhibitory LtßRIg as a candidate biological therapy in demyelinating disorders, because it is beneficial during both demyelination and remyelination.
Key words: demyelination; cuprizone; glia; Lt
ß; LtßR; therapy
Received July 24, 2006;
revised June 1, 2007;
accepted June 4, 2007.
Correspondence should be addressed to Dr. Jenny P.-Y. Ting, Lineberger Comprehensive Cancer Center, Campus Box 7295, University of North Carolina, Chapel Hill, NC 27599. Email: panyun{at}med.unc.edu
This article has been cited by other articles:

|
 |

|
 |
 
M. Dubois-Dalcq, A. Williams, C. Stadelmann, B. Stankoff, B. Zalc, and C. Lubetzki
From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
Brain,
July 1, 2008;
131(7):
1686 - 1700.
[Abstract]
[Full Text]
[PDF]
|
 |
|